Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications

Introduction: Checkpoint kinase 2 (CHEK2) is a moderate penetrance breast cancer risk gene, whose truncating mutation 1100delC increases the risk about twofold. We investigated gene copy-number aberrations and geneexpression profiles that are typical for breast tumors of CHEK2 1100delC-mutation carriers. Methods: In total, 126 breast tumor tissue specimens including 32 samples from patients carrying CHEK2 1100delC were studied in array-comparative genomic hybridization (aCGH) and gene-expression (GEX) experiments. After dimensionality reduction with CGHregions R package, CHEK2 1100delC-associated regions in the aCGH data were detected by the Wilcoxon rank-sum test. The linear model was fitted to GEX data with R package limma. Genes whose expression levels were associated with CHEK2 1100delC mutation were detected by the bayesian method. Results: We discovered four lost and three gained CHEK2 1100delC-related loci. These include losses of 1p13.3-31.3, 8p21.1-2, 8p23.1-2, and 17p12-13.1 as well as gains of 12q13.11-3, 16p13.3, and 19p13.3. Twenty-eight genes located on these regions showed differential expression between CHEK2 1100delC and other tumors, nominating them as candidates for CHEK2 1100delC-associated tumor-progression drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM, and LRP1 on 12q13. Altogether, 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44, reduced expression levels. Our results suggest the WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC-mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC-associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy-number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions, we identified potential drivers of CHEK2 1100delC-associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene-expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of the CHEK2 1100delC mutation.

[1]  L. O’Driscoll.  Gene Expression Profiling , 2011, Methods in Molecular Biology.

[2]  J. Murnane,et al.  Telomere loss as a mechanism for chromosome instability in human cancer. , 2010, Cancer research.

[3]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[4]  I. Petersen,et al.  The CHK2–BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells , 2010, Nature Cell Biology.

[5]  David Haussler,et al.  The UCSC Genome Browser database: update 2010 , 2009, Nucleic Acids Res..

[6]  Stephen Fox,et al.  Subtypes of familial breast tumours revealed by expression and copy number profiling , 2010, Breast Cancer Research and Treatment.

[7]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[8]  Jari Häkkinen,et al.  BASE - 2nd generation software for microarray data management and analysis , 2009, BMC Bioinformatics.

[9]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  David Pellman,et al.  A Mechanism Linking Extra Centrosomes to Chromosomal Instability , 2009, Nature.

[11]  Hanns Hatt,et al.  Activation of an Olfactory Receptor Inhibits Proliferation of Prostate Cancer Cells* , 2009, The Journal of Biological Chemistry.

[12]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Ashworth,et al.  Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  G. Smyth,et al.  Microarray background correction: maximum likelihood estimation for the normal–exponential convolution , 2008, Biostatistics.

[15]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[16]  N. Crawford,et al.  The origins of breast cancer prognostic gene expression profiles. , 2009, Cancer research.

[17]  Yehudit Hasin,et al.  High-Resolution Copy-Number Variation Map Reflects Human Olfactory Receptor Diversity and Evolution , 2008, PLoS genetics.

[18]  Carlos Caldas,et al.  High-resolution array CGH clarifies events occurring on 8p in carcinogenesis , 2008, BMC Cancer.

[19]  Steinar Lundgren,et al.  CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer , 2008, PloS one.

[20]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[21]  B. Trask,et al.  Extensive copy-number variation of the human olfactory receptor gene family. , 2008, American journal of human genetics.

[22]  M. A. van de Wiel,et al.  Weighted clustering of called array CGH data. , 2008, Biostatistics.

[23]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[24]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[25]  E. Leygue,et al.  Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers , 2008, Histopathology.

[26]  Olga Anczuków,et al.  Does the nonsense‐mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? , 2008, Human mutation.

[27]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[28]  M. Cole,et al.  Turning the Tables: Myc Activates Wnt in Breast Cancer , 2007, Cell cycle.

[29]  Johan Staaf,et al.  Normalization of array-CGH data: influence of copy number imbalances , 2007, BMC Genomics.

[30]  L. Vosshall,et al.  Genetic variation in a human odorant receptor alters odour perception , 2007, Nature.

[31]  Yutaka Matsuda,et al.  Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation , 2007, Breast Cancer Research.

[32]  Gordon K. Smyth,et al.  A comparison of background correction methods for two-colour microarrays , 2007, Bioinform..

[33]  Johan Staaf,et al.  High‐resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization , 2007, Genes, chromosomes & cancer.

[34]  Wessel N. van Wieringen,et al.  CGHcall: calling aberrations for array CGH tumor profiles , 2007, Bioinform..

[35]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[36]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[37]  Wessel N. van Wieringen,et al.  CGHregions: Dimension Reduction for Array CGH Data with Minimal Information Loss , 2007 .

[38]  J. Peterse,et al.  Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Klijn,et al.  Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study , 2007, Breast Cancer Research.

[40]  I. Campbell,et al.  Genetic and Epigenetic Analysis of CHEK2 in Sporadic Breast, Colon, and Ovarian Cancers , 2006, Clinical Cancer Research.

[41]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[42]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[43]  H. Nevanlinna,et al.  The CHEK2 gene and inherited breast cancer susceptibility , 2006, Oncogene.

[44]  R. Eeles,et al.  Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. , 2006, Cancer research.

[45]  D. Lancet,et al.  Widespread ectopic expression of olfactory receptor genes , 2006, BMC Genomics.

[46]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[47]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[48]  Jeong Hoon Kim,et al.  Differential Use of Functional Domains by Coiled-coil Coactivator in Its Synergistic Coactivator Function with β-Catenin or GRIP1* , 2006, Journal of Biological Chemistry.

[49]  Terrence S. Furey,et al.  The UCSC Genome Browser Database: update 2006 , 2005, Nucleic Acids Res..

[50]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[51]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[52]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[53]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[55]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[56]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[57]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[58]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[59]  S. Geisler,et al.  Alternative splicing and mutation status of CHEK2 in stage III breast cancer , 2004, Oncogene.

[60]  O. Watanabe,et al.  Expression of twist and wnt in human breast cancer. , 2004, Anticancer research.

[61]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[62]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[63]  P. Mombaerts,et al.  A Contextual Model for Axonal Sorting into Glomeruli in the Mouse Olfactory System , 2004, Cell.

[64]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[65]  K. Sossey-Alaoui,et al.  CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer , 2004, Oncogene.

[66]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[67]  J. Reed,et al.  Bcl-2 Gene Family and Related Proteins in Mammary Gland Involution and Breast Cancer , 1999, Journal of Mammary Gland Biology and Neoplasia.

[68]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.

[69]  J. Klijn,et al.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.

[70]  Terry Speed,et al.  Normalization of cDNA microarray data. , 2003, Methods.

[71]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  T. Speed,et al.  Statistical issues in cDNA microarray data analysis. , 2003, Methods in molecular biology.

[73]  M. Katoh,et al.  WNT and FGF gene clusters (review). , 2002, International journal of oncology.

[74]  R. Eeles,et al.  CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours , 2002, British Journal of Cancer.

[75]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[76]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[77]  R. DePinho,et al.  Connecting chromosomes, crisis, and cancer. , 2002, Science.

[78]  S. Gruvberger,et al.  BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data , 2002, Genome Biology.

[79]  L. Murphy,et al.  Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. , 2002, Cancer research.

[80]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[81]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[82]  S. Firestein.  How the olfactory system makes sense of scents , 2001, Nature.

[83]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[85]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[86]  Alexander Kinev,et al.  BRCA1 Is Associated with a Human SWI/SNF-Related Complex Linking Chromatin Remodeling to Breast Cancer , 2000, Cell.

[87]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[88]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[89]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[90]  A. Gruber,et al.  Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. , 1999, American journal of physiology. Cell physiology.

[91]  J. Jónasson,et al.  Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival , 1999, British Journal of Cancer.

[92]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[93]  W. Dreyer,et al.  The area code hypothesis revisited: olfactory receptors and other related transmembrane receptors may function as the last digits in a cell surface code for assembling embryos. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  A. Harris,et al.  Compartment switching of WNT-2 expression in human breast tumors. , 1996, Cancer research.

[95]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[96]  B. Ljung,et al.  Heterogeneity for allelic loss in human breast cancer. , 1992, Journal of the National Cancer Institute.